The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML-Reference-Cited by-同舟云学术

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

Published:2012-05-29 Issue:4 Volume:158 Page:519-522
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Burnett Alan K.¹,Russell Nigel H.²,Culligan Dominic³,Cavanagh Jamie⁴,Kell Jonathan⁵,Wheatley Keith⁶,Virchis Andra⁷,Hills Robert K.¹,Milligan Donald⁸,

Affiliation:

1. Department of Haematology; Cardiff University School of Medicine; Cardiff; UK

2. Department of Haematology; Nottingham City Hospital; Nottingham; UK

3. Department of Haematology; Aberdeen Royal Infirmary; Aberdeen; UK

4. Department of Haematology; Bart's and the London NHS Trust; London; UK

5. Department of Haematology; University Hospital of Wales; Cardiff; UK

6. Cancer Research UK Clinical Trials Unit; School of Cancer Sciences; University of Birmingham; Birmingham; UK

7. Department of Haematology; Barnet Hospital; Hertfordshire; UK

8. Department of Haematology; Birmingham Heartlands Hospital; Birmingham; UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2012.09165.x/fullpdf

Reference13 articles.

1. Lipid posttranslational modifications. Farnesyl transferase inhibitors;Basso;Journal of Lipid Research,2006

2. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment;Burnett;Cancer,2007

3. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma;Cohen;Journal of Clinical Oncology,2003

4. Farnesyl transferase inhibitors: promises and realities;Cox;Current Opinion in Chemical Biology,2002

5. Characterization of the antitumor effects of the selective farnesyl protein transfease inhibitor R115777 in vivo and in vitro;End;Cancer Research,2001

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

2. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma;Oncogene;2022-04-22

3. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial;Leukemia Research;2021-12

4. A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial;British Journal of Haematology;2021-05-07

5. The importance of Ras in drug resistance in cancer;British Journal of Pharmacology;2021-04-06